ERRATUM

Erratum to: The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials

Benlei Li¹ · Dong Fang¹ · Cheng Qian¹ · Hongliang Feng² · Yanggan Wang¹

Published online: 22 February 2017
© Springer International Publishing Switzerland 2017

Erratum to: Clin Drug Investig
DOI 10.1007/s40261-016-0470-3

In the original publication, Figs. 3, 4, 5 and 6 were labelled incorrectly. Below are the correct versions of Figs. 3, 4, 5 and 6:

The online version of the original article can be found under doi:[10.1007/s40261-016-0470-3](https://doi.org/10.1007/s40261-016-0470-3).

✉ Yanggan Wang
wb000813@whu.edu.cn

¹ Department of Cardiology, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuhan 430071, Hubei, China

² Department of Neurology, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuhan 430071, Hubei, China

Fig. 3 Effect of tolvaptan on changes in serum sodium concentrations (a) and serum sodium correction rates (b) in patients with hyponatremia. CI confidence interval, df degrees of freedom, IV inverse variance, $M-H$ Mantel-Haenszel, SD standard deviation

Fig. 4 Effect of tolvaptan on 24-h urine output (a) and net fluid balance (b) in patients with hyponatremia. CI confidence interval, df degrees of freedom, IV inverse variance, SD standard deviation

Fig. 5 Impact of tolvaptan on adverse event rates (a) and serious adverse event rates (b) in patients with hyponatremia. *CI* confidence interval, *df* degrees of freedom, *M-H* Mantel-Haenszel

Fig. 6 Impact of tolvaptan on changes in systolic blood pressure (a) and changes in heart rate (b) in patients with hyponatremia. *CI* confidence interval, *df* degrees of freedom, *IV* inverse variance, *SD* standard deviation